MK-677 vs GHRP-2: A Non-Peptide Oral Compound and a Peptide, Compared
MK-677 (ibutamoren, oral non-peptide) vs GHRP-2 (pralmorelin, peptide): the same receptor, different chemistry and different human evidence. A research-literacy comparison of what has been studied.
| Feature | MK-677 | GHRP-2 |
|---|---|---|
| Chemical class | Non-peptide small molecule | Synthetic hexapeptide |
| Receptor | GHS-R1a (ghrelin receptor) | GHS-R1a (ghrelin receptor) |
| Routes used in human studies | By mouth, once daily in adult trials (2 to 50 mg) | Intravenous test doses; subcutaneous injection for 5 days in one study; infusions of 5 to 30 days; oral, intranasal and subcutaneous routes in children |
| Half-life in people | Not established; none found | 0.55 hours (about 33 minutes) after one intravenous dose in 10 children (PMID 9543135) |
| GH and IGF-1 in people | 25 mg a day raised mean 24-hour GH 97% and IGF-I into the young-adult range over 2 to 4 weeks in healthy older adults (PMID 8954023); IGF-1 rose 72.9% at 12 months in an Alzheimer's trial (PMID 19015485) | Five days of 100 µg subcutaneously: response attenuation and no rise in IGF-I (PMID 9820615). A 30-day continuous infusion raised IGF-1 (PMID 11322505). |
| Largest trials found | 563 people with Alzheimer's disease (12 months); 292 women with low bone density (18-month study); 123 hip-fracture patients (24 weeks) | 126 children with GH deficiency (intranasal, 48 weeks, PMID 25374440) |
| Clinical outcomes | Fat-free mass +1.1 kg against -0.5 kg in healthy older adults, with no significant change in visceral fat, strength or function (PMID 18981485); Alzheimer's progression not slowed (PMID 19015485); hip-fracture trial stopped early over a congestive heart failure signal (PMID 21067829) | No growth benefit in 126 children (PMID 25374440); used as a one-off diagnostic test in adults (PMID 17609397) |
| Bone evidence | Bone-turnover markers rose (PMID 10404019). With alendronate, femoral neck BMD rose 4.2% against 2.5% on alendronate alone, but not at other sites (PMID 11238495). | No bone density study in the 2 November 2026 PubMed search for GHRP-2 human studies; osteocalcin, a marker of bone formation, rose after 5 days of daily injection in 9 healthy subjects (PMID 9820615) and with GHRP-2 plus TRH in critically ill patients (PMID 10199772) |
| Safety signals reported | Heart failure signal, higher fasting glucose, oedema, appetite, muscle pain | Raised prolactin, ACTH and cortisol in young adults (PMID 9285939); increased food intake |
| Regulatory label | None found (DailyMed, 6 November 2026); a phase 3 trial of ibutamoren mesylate in children with GH deficiency was listed as recruiting (NCT06948214) | None found in the US (DailyMed, 6 November 2026). A 2013 Japanese study says a GHRP-2 test is recommended in Japan as an alternative for diagnosing adult GH deficiency (PMID 23079545). |
| FDA bulk drug substances page (content current as of 22 April 2026) | Ibutamoren mesylate in category 2 under the 503A (added 29 September 2023) and 503B (added 29 December 2022) interim policies. FDA safety statement: see Safety signals compared | Category 2 under the 503B interim policy for injectable and nasal routes (added 29 September 2023). FDA safety statement: see Safety signals compared |
| WADA 2026 Prohibited List | Named under S2.2.4 (ibutamoren, MK-677) | Named under S2.2.4 (GHRP-2, pralmorelin) |
Mechanism side by side
Both compounds act at the same receptor, GHS-R1a, the ghrelin receptor. The difference between them is chemistry and the way each has been studied.
MK-677 is a non-peptide, orally active ghrelin mimetic (PMID 18981485). In healthy older adults it increased growth hormone (GH) through "an enhancement of preexisting pulsatile GH secretion", raising pulse height and the low points between pulses without a significant change in the number of pulses (PMID 8954023). No human half-life was found.
GHRP-2 is a synthetic hexapeptide. A 2004 drug profile calls pralmorelin "an orally active, synthetic growth hormone-releasing peptide" (PMID 15230633), and 10 children with GH deficiency took 900 µg/kg by mouth twice daily for 12 months (PMID 14513874), a per-kilogram figure that is not comparable with adult MK-677 doses. It has also been given intravenously, by subcutaneous injection and infusion, and intranasally. After a single 1 µg/kg intravenous dose in 10 children of short stature, its terminal half-life was 0.55 hours, about 33 minutes (PMID 9543135).
Evidence base: head-to-head versus separate trials
A PubMed search on 3 November 2026 for (MK-677 OR ibutamoren) AND (GHRP-2 OR pralmorelin) returned nine records: eight reviews and one receptor-binding study. None is a trial comparing the two.
MK-677 has randomised trials in several populations.
- In 32 healthy adults aged 64 to 81, 25 mg a day raised serum IGF-I (insulin-like growth factor I) into the normal range for young adults (PMID 8954023).
- In a trial with a 2-year design in 65 healthy older adults, fat-free mass changed by +1.1 kg on MK-677 against -0.5 kg on placebo, but visceral fat did not differ significantly, and "increased fat-free mass did not result in changes in strength or function". Fasting glucose rose and insulin sensitivity decreased (PMID 18981485).
- In 563 people with Alzheimer's disease, IGF-1 rose 72.9% at 12 months but the drug was ineffective at slowing progression (PMID 19015485).
- In women with low bone density, MK-677 plus alendronate raised femoral neck bone mineral density (4.2% against 2.5% on alendronate alone) but not density at the lumbar spine, total hip or total body, in an 18-month study (PMID 11238495). Bone-turnover markers rose in healthy and functionally impaired older adults (PMID 10404019).
See the MK-677 monograph for the full list, including registered trials.
GHRP-2 has diagnostic-test studies, injection and infusion studies of 5 to 30 days (some placebo-controlled, in critically ill patients) and trials in children (PMID 17609397; PMID 9820615; PMID 10199772; PMID 11322505; PMID 25374440). The 48-week intranasal trial in 126 children with GH deficiency found no growth benefit. See the GHRP-2 monograph.
A 2018 review covers growth hormone secretagogues as a class, including small-molecule and peptide agents, and does not rank individual compounds by safety (PMID 28400207).
Clinical use
Neither compound has a general clinical indication in the sources we read. The MK-677 trials were in specific populations: a hip-fracture trial was terminated early because of a congestive heart failure signal, with the authors concluding that MK-0677 had an unfavourable safety profile in that population (PMID 21067829), and the Alzheimer's trial was negative (PMID 19015485). For GHRP-2, a 2013 Japanese study states that "the glucagon, arginine, and GH releasing peptide-2 (GHRP-2) test are recommended as alternatives in Japan" for diagnosing adult GH deficiency (PMID 23079545), and a 2004 drug profile reported pralmorelin awaiting approval in Japan as a diagnostic agent and said US development for GH deficiency appeared to have been discontinued (PMID 15230633). No Japanese approval document was found.
Safety signals compared
The two have been studied at different depths and over different periods, so the signals cannot be ranked.
- MK-677: a congestive heart failure signal in hip-fracture patients (PMID 21067829); fasting glucose rose in healthy older adults and glucose handling was impaired in obese men (PMID 8954023; PMID 9467542); transient oedema, increased appetite and muscle pain (PMID 18981485).
- GHRP-2: prolactin, ACTH and cortisol rose in six young adults (PMID 9285939); food intake rose in healthy men (PMID 15699539); the GH response attenuated over 5 days of daily injection (PMID 9820615).
- Both: a 2018 review reported few long-term, rigorously controlled studies of GH secretagogues and concluded that long-term safety, including cancer incidence and mortality, still needs to be studied (PMID 28400207).
FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) lists ibutamoren mesylate in category 2 under the 503A interim policy (added 29 September 2023) and the 503B interim policy (added 29 December 2022), and "Growth hormone releasing peptide-2 (GHRP-2) (for injectable and nasal routes of administration)" in category 2 under the 503B interim policy (added 29 September 2023). Compounding is the preparation of a medicine by a pharmacist or doctor from its ingredients. FDA's entry for ibutamoren mesylate reads: "Ibutamoren mesylate poses significant safety risks due to the potential for congestive heart failure in certain patients. The agency is aware of a randomized, placebo-controlled trial assessing ibutamoren mesylate for the treatment of patients recovering from hip fracture that “was terminated early due to a potential safety signal of congestive heart failure.”" Its entry for GHRP-2 reads: "Compounded drugs containing GHRP-2 for injectable and nasal administration may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. GHRP-2 also contains an unnatural amino acid, which adds to the complexity of peptide characterization. FDA is aware of reports of serious adverse advents [sic] in patients who received GHRP-2, including increased insulin requirement to maintain the blood glucose level, death of critically ill study subjects, infection and pancreatitis, though causality has not been established."
Anti-doping and UK regulatory position
The World Anti-Doping Agency 2026 Prohibited List names ibutamoren (MK-677) among the growth hormone secretagogues and GHRP-2 (pralmorelin) among the growth hormone releasing factors, both under S2.2.4. See Peptides and sports anti-doping. DailyMed name searches on 6 November 2026 returned no label for MK-677 or GHRP-2.
This site gives no legal advice or sourcing information and does not sell anything. Rules on unauthorised medicines exist in the Human Medicines Regulations 2012. Whether a particular product is a medicinal product under regulation 2 depends on its specifics, including how it is presented and how it functions. For questions about medicines speak to a GP or pharmacist; problems with a medicine can be reported to the MHRA through the Yellow Card scheme.
Related pages
- MK-677 monograph
- GHRP-2 monograph
- Ipamorelin monograph: peptide secretagogue comparator
- GH axis mechanism map
- Peptides and sports anti-doping
Verdict — research-question matching
They act at the same receptor but have been studied differently. MK-677 is an oral compound with randomised trials of 4 days to 12 months of treatment in older adults and patients, one with a 2-year design: GH and IGF-1 rose, visceral fat, strength and function did not improve, blood glucose rose, and one trial was stopped over a heart failure signal. GHRP-2 is a peptide whose human work is mostly diagnostic tests, adult injection and infusion studies of 5 to 30 days, a chart review and a one-year case report, and trials in children. No trial compares them, and the literature does not support choosing one over the other for any purpose.
References
Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.
- Chapman IM, Bach MA, et al.. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. 1996;81(12) :4249-4257 · PMID: 8954023
- Svensson J, Lönn L, Jansson JO, et al.. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology and Metabolism. 1998;83(2) :362-9 · PMID: 9467542
- Murphy MG, Bach MA, et al. (MK-677 Study Group). Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. Journal of Bone and Mineral Research. 1999;14(7) :1182-1188 · PMID: 10404019
- Murphy MG, Weiss S, et al.. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Journal of Clinical Endocrinology and Metabolism. 2001;86(3) :1116-1125 · PMID: 11238495
- Nass R, Pezzoli SS, Oliveri MC, et al.. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. 2008;149(9) :601-11 doi:10.7326/0003-4819-149-9-200811040-00003 · PMID: 18981485
- Sevigny JJ, Ryan JM, van Dyck CH, et al.. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008;71(21) :1702-8 doi:10.1212/01.wnl.0000335163.88054.e7 · PMID: 19015485
- Adunsky A, Chandler J, Heyden N, et al.. MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study. Archives of Gerontology and Geriatrics. 2011;53(2) :183-9 doi:10.1016/j.archger.2010.10.004 · PMID: 21067829
- n/a. Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. Drugs in R&D. 2004;5(4) :236-239 doi:10.2165/00126839-200405040-00011 · PMID: 15230633
- Chihara K, Shimatsu A, Hizuka N, et al.. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. European Journal of Endocrinology. 2007;157(1) :19-27 doi:10.1530/EJE-07-0066 · PMID: 17609397
- Kinoshita Y, Tominaga A, Usui S, et al.. The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison. Endocrine Journal. 2013;60(1) :97-105 doi:10.1507/endocrj.ej12-0230 · PMID: 23079545
- Arvat E, di Vito L, Maccagno B, et al.. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides. 1997;18(6) :885-91 doi:10.1016/s0196-9781(97)00016-8 · PMID: 9285939
- Pihoker C, Kearns GL, French D, Bowers CY. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. Journal of Clinical Endocrinology and Metabolism. 1998;83(4) :1168-72 doi:10.1210/jcem.83.4.4744 · PMID: 9543135
- Nijland EA, Strasburger CJ, Popp-Snijders C, van der Wal PS, van der Veen EA. A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men. European Journal of Endocrinology. 1998;139(4) :395-401 doi:10.1530/eje.0.1390395 · PMID: 9820615
- Bowers CY, Granda-Ayala R. Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine. 2001;14(1) :79-86 doi:10.1385/ENDO:14:1:079 · PMID: 11322505
- Mericq V, Cassorla F, Bowers CY, Avila A, Gonen B, Merriam GR. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in growth hormone deficient children. Journal of pediatric endocrinology & metabolism : JPEM. 2003;16(7) :981-5 doi:10.1515/jpem.2003.16.7.981 · PMID: 14513874
- Tanaka T, Hasegawa Y, Yokoya S, Nishi Y. Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency. Clinical Pediatric Endocrinology. 2014;23(4) :107-14 doi:10.1297/cpe.23.107 · PMID: 25374440
- Laferrère B, Abraham C, Russell CD, Bowers CY. Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. Journal of Clinical Endocrinology and Metabolism. 2005;90(2) :611-4 doi:10.1210/jc.2004-1719 · PMID: 15699539
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. 2018;6(1) :45-53 doi:10.1016/j.sxmr.2017.02.004 · PMID: 28400207
- Van den Berghe G, Wouters P, Weekers F, et al.. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. Journal of Clinical Endocrinology and Metabolism. 1999;84(4) :1311-23 doi:10.1210/jcem.84.4.5636 · PMID: 10199772
- Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: unsourced half-lives and a wrong oral-bioavailability claim were removed; a heart failure trial signal, null trial results, human GHRP-2 studies and FDA's statements were added; legal statements were replaced.
If you spot an error or have new evidence to suggest, please use our corrections policy.
Continue reading
MK-677 (Ibutamoren) — Oral Ghrelin-Receptor Agonist (Research Evidence Summary)
MK-677 (ibutamoren) is an oral, non-peptide ghrelin-receptor agonist. This summary reviews the randomised trial evidence, the heart failure and glucose signals, and what is unknown.
GHRP-2 — Growth Hormone Releasing Peptide 2 (Research Evidence Summary)
GHRP-2 (pralmorelin) is a synthetic ghrelin-receptor agonist. Human studies range from one-off diagnostic tests to trials in children, and long-term safety is not established.
Ipamorelin vs GHRP-2: Two Ghrelin-Receptor Agonists Compared
Ipamorelin vs GHRP-2: the shared receptor, the swine selectivity finding, the human studies that exist for each, and what is unknown. No human head-to-head trial was found.